1. 1. Pihos AM. Epidemic keratoconjunctivitis: a review of current concepts in management. J Optom. 2013 Apr; 6(2):69-74. Available from: https://doi.org/10.1016/j.optom.2012.08.003 [DOI:10.1016/j.optom.2012.08.003.] []

2. Russell W. Adenoviruses: update on structure and function. J Gen Virol. 2009 Jan; 90(1):1-20. Available from: [DOI:10.1099/vir.0.003087-0] [PMID]

3. Akkaya S, Ozkurt YB. Persistent Symblepharon in an infant following epidemic keratoconjunctivitis. Med Hypothesis Discov Innov Ophthalmol. 2016; 5(3):74.

4. Özen Tunay Z, Ozdemir O, Petricli IS. Povidone iodine in the treatment of adenoviral conjunctivitis in infants. Cutan Ocul Toxicol. 2015 Jan 2; 34(1):12-5. Available from: [DOI:10.3109/15569527.2014.888077] [PMID]

5. Butt AL, Chodosh J. Adenoviral keratoconjunctivitis in a tertiary care eye clinic. Cornea. 2006 Feb 1; 25(2):199-202. Available from [DOI:10.1097/01.ico.0000170693.13326.fb] [PMID]

6. Kaufman HE. Adenovirus advances: new diagnostic and therapeutic options. Curr Opin Ophthalmol. 2011 Jul 1; 22(4):290-3. Available from [DOI:10.1097/ICU.0b013e3283477cb5] [PMID]

7. Kovalyuk N, Kaiserman I, Mimouni M, Cohen O, Levartovsky S, Sherbany H, et al. Treatment of adenoviral keratoconjunctivitis with a combination of povidone‐iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study. Acta Ophthalmol. 2017 Dec; 95(8):e686-e92. Available from: [DOI:10.1111/aos.13416] [PMID]

8. Meyer-Rüsenberg B, Loderstädt U, Richard G, Kaulfers PM, Gesser C. Epidemic keratoconjunctivitis: the current situation and recommendations for prevention and treatment. Dtsch Arztebl Int. 2011 Jan; 108(27):475. Available from: [DOI:10.3238/arztebl.2011.0475] [PMID] []

9. Kulkarni C, Ballal K. A treatment protocol for minimizing duration and complications of adenoviral epidemic keratoconjunctivitis. Taiwan J Ophthalmol. 2020 Oct; 10(4):269. Available from: [DOI:10.4103/tjo.tjo_66_19] [PMID] []

10. Ward JB, Siojo LG, Waller SG. A prospective, masked clinical trial of trifluridine, dexamethasone, and artificial tears in the treatment of epidemic keratoconjunctivitis. Cornea. 1993 May 1; 12(3):216-21. Available from: [DOI:10.1097/00003226-199305000-00006] [PMID]

11. Reibaldi M, Avitabile T, Bandello F, Longo A, Bonfiglio V, Russo A, et al. The effectiveness of 0.6% povidone iodine eye drops in reducing the conjunctival bacterial load and needle contamination in patients undergoing anti-VEGF intravitreal injection: a prospective, randomized study. J Clin Med. 2019 Jul 13; 8(7):1031. Available from: [DOI:10.3390/jcm8071031] [PMID] []

12. Pinna A, Donadu MG, Usai D, Dore S, D'Amico‐Ricci G, Boscia F, et al. In vitro antimicrobial activity of a new ophthalmic solution containing povidone‐iodine 0.6% (IODIM®). Acta Ophthalmol. 2020 Mar; 98(2):e178-e80. Available from: [DOI:10.1111/aos.14243] [PMID]

13. Pelletier J, Stewart K, Trattler W, Ritterband D, Braverman S, Samson C, et al. A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis. Adv Ther. 2009 Aug; 26(8):776-83. Available from: [DOI:10.1007/s12325-009-0062-1] [PMID]

14. Trinavarat A, Atchaneeyasakul L. Treatment of epidemic Keratoconjunctivitis with 2% povidone-iodine: a pilot study. J Ocul Pharmacol Ther. 2012 Feb 1;28(1):53-8. Available from: [DOI:10.1089/jop.2011.0082] [PMID]

15. Lachapelle J-M, Castel O, Casado AF, Leroy B, Micali G, Tennstedt D, et al. Antiseptics in the era of bacterial resistance: a focus on povidone iodine. Clinical Practice. 2013 Sep 1; 10(5):579. [DOI:10.2217/cpr.13.50]

16. Oliverio GW, Spinella R, Postorino EI, Inferrera L, Aragona E, Aragona P. Safety and Tolerability of an Eye Drop Based on 0.6% Povidone-Iodine Nanoemulsion in Dry Eye Patients. J Ocul Pharmacol Ther. 2021 Mar 1; 37(2):90-6. Available from: [DOI:10.1089/jop.2020.0085] [PMID] []

17. Chou SF, Lin CH, Chang SW. Povidone-iodine application induces corneal cell death through fixation. Br J Ophthalmol. 2011 Feb 1; 95(2): 277-83. Available from: http://dx.doi.org/10.1136/bjo.2010.189407 [DOI:10.1136/bjo.2010.189407] [PMID]